Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase I study initiated for REN-001 in McArdle disease

Jan. 22, 2020

Boehringer Ingelheim presents GPR142 agonists

Jan. 22, 2020

Yale University divulges let-7 microRNA-activating compounds for endometriosis

Jan. 22, 2020

FDA clears IND application for KAN-101 for the treatment of celiac disease

Jan. 22, 2020

FDA approves Polaryx's IND for PLX-200 in LINCL

Jan. 21, 2020

Tufts Medical Center divulges CDK6 inhibitors

Jan. 21, 2020

Cord blood cells improve islet transplantation outcomes

Jan. 21, 2020

Oncogenic FHL2-GLI2 fusion identified in sclerosing stromal tumors of the ovary

Jan. 17, 2020

Vertex's VX-814 enters phase II development for alpha1-antitrypsin deficiency

Jan. 16, 2020

New PCSK9 inhibitors discovered at Ra Pharmaceuticals

Jan. 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...